Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — H1 2026 Earnings Presentation
17 slides from Oncoinvent Asa's earnings presentation, Aug 27, 2026
Slide 1: First Half-Year Presentation
Transforming cancer care through direct alpha therapy First Half-Year Presentation 27 August 2026 · Euronext Oslo: ONCIN
Slide 2: Today’s presenters
Today’s presenters Oystein Soug Ramzi Amri Chief Executive Officer Chief Financial Officer 2
Slide 3: Disclaimer and important information
Disclaimer and important information This presentation (the “Presentation”) has been prepared by Oncoinvent ASA (the “Company”) for information purposes only and does not constitute, and should not be construed as, an offer to sell, or a solicitation of an offer to buy, any securities of the Company
Slide 4: What we will cover today
What we will cover today Highlights 1 Delivering against our 2026 priorities CEO Radspherin and the opportunity 2 Value proposition, pipeline and indications CEO Clinical progress 3 Phase 2 ovarian recruitment CEO Financials 4 1H 2026 result, cash position and runway CFO Outlook 5 Phase 3 preparatio
Slide 5: Strong momentum and operational execution
Strong momentum and operational execution o Included four additional sites in Oncoinvent’s Phase 2 trial o Recruited a total of 55 patients into the ovarian Phase 2 trial, passing the half-way mark of trial recruitment o Secured new patent expanding protection for Radspherin® Radspherin® o Presented
Slide 6: Delivering against our 2026 priorities
Delivering against our 2026 priorities ✓ Build momentum in Phase 2 Crossed halfway mark,Q2 was the best quarter to DELIVERED recruitment date Four sites added in 1H26: Italy, UK and Spain (2). ✓ Expand the trial site network DELIVERED Ten now active, more to come All selected amendments approved and
Slide 7: What we will cover today
What we will cover today Highlights 1 Delivering against our 2026 priorities CEO Radspherin and the opportunity 2 Value proposition, pipeline and indications CEO Clinical progress 3 Phase 2 ovarian recruitment CEO Financials 4 1H 2026 result, cash position and runway CFO Outlook 5 Phase 3 preparatio
Slide 8: Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy
Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy Oncoinvent develops Radspherin®, a receptor- Cancer in the abdominal cavity is an independent alpha radiopharmaceutical that area with high unmet need and few eradicates cancer cells in the abdominal cavity good tr
Slide 9: Radspherin® addresses a large high-risk patient population with no effective treatment option
Radspherin® addresses a large high-risk patient population with no effective treatment option search 2025 Radspherin Value Pillars Radspherin Benefits Targeting a High-Need Patient Population Patients with peritoneal metastases are at Ovarian cancer provides an high-risk of disease recurrence, even
Slide 10: Ovarian cancer focus, same drug leveraged into CRC
Ovarian cancer focus, same drug leveraged into CRC 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 RAD-18-001 Ovarian, recurrent phase 1 RAD-18-002 Colorectal phase 1/2a RAD-18-003 Ovarian, primary phase 2 Interim Interim Final (>9mth FU) RAD-18-004 Submission Colorectal target: 2030 phase 21 RAD-18-005 Ova
Slide 11: Recruitment momentum improved in 2026
Recruitment momentum improved in 2026 10 hospitals active Momentum remains strong o In addition to the original six, in 1H26 o Despite two weeks scheduled four new hospitals were added manufacturing halt for maintenance during summer, Q3 started well Effective amendments o Selected protocol amendmen
Slide 12: Patient recruitment momentum continues to accelerate
Patient recruitment momentum continues to accelerate Patients recruited, incl. safety run-in Patients recruited Active sites Q2 2026 recruitment H1 2026 recruitment 55 10 18 29 To date, crossed halfway Four new sites added in Best quarter to date More than full year 2025 point 1H26 18 11 8 7 4 1 Q1
Slide 13: What we will cover today
What we will cover today Highlights 1 Delivering against our 2026 priorities CEO Radspherin and the opportunity 2 Value proposition, pipeline and indications CEO Clinical progress 3 Phase 2 ovarian recruitment CEO Financials 4 1H 2026 result, cash position and runway CFO Outlook 5 Phase 3 preparatio
Slide 14: Summary of financials
Summary of financials Cash position Operating result Operating cash burn Runway NOK 108.8m NOK (69.0)m NOK (69.3)m Into 2027 incl. restricted, 30 Jun 2026 vs NOK (52.0)m in 1H 2025 in line with Board budget past the interim readout NOK m 1H 25 2H 25 1H 26 Total operating revenues 12 16 8 Scaled with
Slide 15: What we will cover today
What we will cover today Highlights 1 Delivering against our 2026 priorities CEO Radspherin and the opportunity 2 Value proposition, pipeline and indications CEO Clinical progress 3 Phase 2 ovarian recruitment CEO Financials 4 1H 2026 result, cash position and runway CFO Outlook 5 Phase 3 preparatio
Slide 16: Looking ahead: preparing for Phase 3
Looking ahead: preparing for Phase 3 We are encouraged by the safety profile and clinical signals observed in our early phase studies, and are confident these signals will be confirmed to date in the randomized, controlled Phase 2 ovarian cancer trial, which continues to recruit. Interim analyses wi
Slide 17: Upcoming events: meet the team
Upcoming events: meet the team 8-9 September NLSD: Nordic Life Science Days, Stockholm 17 September Oppenheimer Targeted Radiopharmaceutical therapies summit, NYC 30 September CF&B Communication's European Midcap Event, Paris 17-21 October EANM (European Association of Nuclear Medicine) Congress, Vi